Drug Profile
NT 503
Alternative Names: Encapsulated VEGF inhibitor - Neurotech; NT-503; NT-503-2; NT-503-3; Wet AMD encapsulated cell therapy - NeurotechLatest Information Update: 14 Jun 2018
Price :
$50
*
At a glance
- Originator Neurotech USA
- Class Cell therapies; Eye disorder therapies
- Mechanism of Action Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Choroidal neovascularisation
Most Recent Events
- 14 Jun 2018 Discontinued - Phase-II for Choroidal neovascularisation (Recurrent, Treatment-experienced) in Israel (Intraocular) (Neurotech USA pipeline, June 2018)
- 14 Jun 2018 Discontinued - Phase-II for Choroidal neovascularisation (Recurrent, Treatment-experienced) in USA (Intraocular) (Neurotech USA pipeline, June 2018)
- 18 Oct 2016 Neurotech USA terminates phase II portion of a phase I/II trial in Choroidal neovascularisation (Recurrent, Treatment-experienced) in USA and Israel (Neurotech USA pipeline, July 2016)